Bringhen, S., & Goldschmidt, H. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib: A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Journal of internal medicine, 286(1), . https://doi.org/10.1111/joim.12882
Chicago-Zitierstil (17. Ausg.)Bringhen, Sara, und Hartmut Goldschmidt. "Prevention, Monitoring and Treatment of Cardiovascular Adverse Events in Myeloma Patients Receiving Carfilzomib: A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension." Journal of Internal Medicine 286, no. 1 (2019). https://doi.org/10.1111/joim.12882.
MLA-Zitierstil (9. Ausg.)Bringhen, Sara, und Hartmut Goldschmidt. "Prevention, Monitoring and Treatment of Cardiovascular Adverse Events in Myeloma Patients Receiving Carfilzomib: A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension." Journal of Internal Medicine, vol. 286, no. 1, 2019, https://doi.org/10.1111/joim.12882.